The Impact of Analgesic Medication on Quality of Life Among Rheumatoid Arthritis Patients
DOI:
https://doi.org/10.54112/bcsrj.v7i1.2079Keywords:
Anti-Citrullinated Protein Antibodies, Cyclooxygenase-2, Disease-Modifying Antirheumatic Drugs, Genome-Wide Association Studies, Interleukins, Rheumatoid ArthritisAbstract
Rheumatoid arthritis is a chronic autoimmune inflammatory disorder that substantially compromises physical function, mental well-being, and health-related quality of life. Objective: To assess health-related quality of life in patients with rheumatoid arthritis using the EuroQol-5D instrument and to evaluate treatment-related outcomes. Methods: A descriptive cross-sectional study was conducted among 25 patients diagnosed with rheumatoid arthritis attending the Outpatient Department of Fuji Foundation Hospital. Data were collected over a defined study period using the EuroQol-5D questionnaire to evaluate mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Information regarding pharmacological treatment was also recorded. Statistical analysis was performed using descriptive statistics, and results were expressed as frequencies and percentages. Results: The analysis demonstrated marked impairment across all EuroQol-5D domains, particularly in pain or discomfort and limitations in usual activities. Regarding treatment patterns, 16% of patients were receiving disease-modifying antirheumatic drugs, 52% were on analgesic monotherapy, and 24% were treated with a combination of analgesics and disease-modifying antirheumatic drugs. Patients receiving combination therapy showed better therapeutic outcomes and higher quality-of-life scores than those on monotherapy. Conclusion: Rheumatoid arthritis significantly impairs health-related quality of life across physical and psychological domains. Combination therapy with analgesics and disease-modifying antirheumatic drugs appears to be associated with improved outcomes. Comprehensive management strategies addressing both physical symptoms and mental health are essential to enhance the quality of life in patients with rheumatoid arthritis.
Downloads
References
Sharif K, Sharif A, Jumah F, Oskouian R, Tubbs RS. Rheumatoid arthritis in review: clinical, anatomical, cellular, and molecular points of view. Clin Anat. 2018;31(2):216-223. https://doi.org/10.1002/ca.23028
Bhattaram P, Chandrasekharan U. The joint synovium: a critical determinant of articular cartilage fate in inflammatory joint diseases. Semin Cell Dev Biol. 2017;62:86-93. https://doi.org/10.1016/j.semcdb.2016.05.007
Ferucci ED, Templin DW, Lanier AP. Rheumatoid arthritis in American Indians and Alaska Natives: a review of the literature. Semin Arthritis Rheum. 2005;34(4):662-667. https://doi.org/10.1016/j.semarthrit.2004.08.003
Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl 1):1-12. https://doi.org/10.2165/00019053-200422001-00002
Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:34. https://doi.org/10.1186/s41927-019-0080-9
Gullick NJ, Ibrahim F, Scott IC, Vincent A, Cope AP, Garrood T, et al. Real-world long-term impact of intensive treatment on disease activity, disability, and health-related quality of life in rheumatoid arthritis. BMC Rheumatol. 2019;3:6. https://doi.org/10.1186/s41927-019-0054-y
Nurchis MC, Sessa G, Pascucci D, Sassano M, Lombi L, Damiani G. Interprofessional collaboration and diabetes management in primary care: a systematic review and meta-analysis of patient-reported outcomes. J Pers Med. 2022;12(4):643. https://doi.org/10.3390/jpm12040643
Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, et al. B Cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects. Front Immunol. 2021;12:750753. https://doi.org/10.3389/fimmu.2021.750753
Markovics A, Rosenthal KS, Mikecz K, Carambula RE, Ciemielewski JC, Zimmerman DH. Restoring the balance between pro-inflammatory and anti-inflammatory cytokines in the treatment of rheumatoid arthritis: new insights from animal models. Biomedicines. 2021;10(1):44. https://doi.org/10.3390/biomedicines10010044
Frazzei G, van Vollenhoven RF, de Jong BA, Siegelaar SE, van Schaardenburg D. Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes. Front Immunol. 2022;13:899372. https://doi.org/10.3389/fimmu.2022.899372
Mueller AL, Payandeh Z, Mohammadkhani N, Mubarak SM, Zakeri A, Alagheband Bahrami A, et al. Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells. 2021;10(11):3017. https://doi.org/10.3390/cells10113017
Konzett V, Aletaha D. Management strategies in rheumatoid arthritis. Nat Rev Rheumatol. 2024;20(12):760-769. https://doi.org/10.1038/s41584-024-01169-7
Ghazanfari MR, Sepehrnia S. Reviewing advances in rheumatoid arthritis treatment: from disease-modifying antirheumatic drugs to innovative drug delivery systems. Immunoregulation. 2024;6(2):105-118. https://doi.org/10.32598/Immunoregulation.6.2.4
Chi XK, Xu XL, Chen BY, Su J, Du YZ. Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments. J Nanobiotechnology. 2023;21(1):105. https://doi.org/10.1186/s12951-023-01857-8
Amer M, Ahmed S, Akhlaq M, Bibi H, Ishfaq M, Arshad MN, et al. Assessment of health-related quality of life among patients of rheumatoid arthritis in Rawalpindi: a cross-sectional study. Clin Epidemiol Glob Health. 2025;35:102151. https://doi.org/10.1016/j.cegh.2025.102151
Singh G, Mahajan N, Abrol S, Raina A. Anxiety and depression are common in rheumatoid arthritis and correlate with poor quality of life in Indian patients. Reumatologia. 2021;59(6):386-393. https://doi.org/10.5114/reum.2021.112351
Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P, Srisomnuek A. Prevalence of and factors associated with depression and anxiety in patients with rheumatoid arthritis: a multicenter prospective cross-sectional study. Int J Rheum Dis. 2020;23(3):302-308. https://doi.org/10.1111/1756-185X.13781
Baliga S, Samant R, Balakrishnan C. Mental health and rheumatoid arthritis. Ann Rheum Dis. 2023;82(Suppl 1):1351-1352. https://doi.org/10.1136/annrheumdis-2023-eular.6117
Ionescu C, Popescu C, Agache M, Dinache G, Codreanu C. Depression in rheumatoid arthritis: prevalence and effects on disease activity. J Clin Med. 2024;13(7):2058. https://doi.org/10.3390/jcm13072058
Isnardi CA, Capelusnik D, Schneeberger EE, Bazzarelli M, Berloco L, Blanco E, et al. Depression is a major determinant of functional capacity in rheumatoid arthritis. J Clin Rheumatol. 2021;27(6 Suppl): S180-S185. https://doi.org/10.1097/RHU.0000000000001506
Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review. Front Public Health. 2021;9:675523. https://doi.org/10.3389/fpubh.2021.675523
Haridoss M, Bagepally BS, Natarajan M. Health-related quality of life in rheumatoid arthritis: systematic review and meta-analysis of EuroQoL EQ-5D utility scores from Asia. Int J Rheum Dis. 2021;24(3):314-326. https://doi.org/10.1111/1756-185X.14066
Zhang S, Chen Y, Wang Y, Wang H, Yao D, Chen G. Tau accumulation in the spinal cord contributes to chronic inflammatory pain by upregulation of IL-1β and BDNF. Neurosci Bull. 2024;40(4):466-482. https://doi.org/10.1007/s12264-023-01152-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ayesha Nasir, Muqqadas Nawaz, Eesha Tariq Bhatty, Noor Saba Khadim Jan, Javeria Shehzadi, Samia Shaukat, Hafiz Abdul Jabbar Siddiqui, Omer Mahmood Mumtaz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
